Our findings demonstrated that, for the first time, PDE5 inhibitor use is associated with significantly reduced mortality in patients with T2DM, an effect which remained after multiple adjustments for known confounding factors. The gene discussed is PDE5A; the disease is type 2 diabetes mellitus.